AiCuris Presents Preclinical and Phase 1 Data of its Anti-HSV Drug AIC316
Read time:
AiCuris announced the presentation of preclinical and Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands, from 7th – 9th of November 2010. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing.
AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the pharmacokinetic-pharmacodynamic relationship of AIC316 by presenting efficacy data from experiments performed in a murine infection model and Phase 1 pharmacokinetic data which demonstrate that the predicted efficacious concentrations of AIC316 will be easily achieved in humans.
The oral presentation will be held during Plenary Session 5 on “Antiviral Resistance” scheduled for Monday, November 8, 2010, at 14:40 hrs, NH Grand Hotel Krasnapolsky, Amsterdam.
“The results also clearly confirm that AIC316 has the potential for once daily dosing which we consider as a prerequisite for the intended indication of genital herpes” said Dr. Holger Zimmermann, Chief Scientific Officer of AiCuris. AiCuris’ CEO Prof.
Helga Rübsamen-Schaeff adds: “Genital and labial herpes may be considered as “unimportant” infectious diseases as they are normally self-limiting and there are drugs to treat them. However, we know that patients may suffer tremendously, physically and psychologically and that the unmet medical need is still very high. Therefore we are committed to make a real difference with an innovative and resistance-breaking drug against Herpes simplex."
AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the pharmacokinetic-pharmacodynamic relationship of AIC316 by presenting efficacy data from experiments performed in a murine infection model and Phase 1 pharmacokinetic data which demonstrate that the predicted efficacious concentrations of AIC316 will be easily achieved in humans.
The oral presentation will be held during Plenary Session 5 on “Antiviral Resistance” scheduled for Monday, November 8, 2010, at 14:40 hrs, NH Grand Hotel Krasnapolsky, Amsterdam.
“The results also clearly confirm that AIC316 has the potential for once daily dosing which we consider as a prerequisite for the intended indication of genital herpes” said Dr. Holger Zimmermann, Chief Scientific Officer of AiCuris. AiCuris’ CEO Prof.
Helga Rübsamen-Schaeff adds: “Genital and labial herpes may be considered as “unimportant” infectious diseases as they are normally self-limiting and there are drugs to treat them. However, we know that patients may suffer tremendously, physically and psychologically and that the unmet medical need is still very high. Therefore we are committed to make a real difference with an innovative and resistance-breaking drug against Herpes simplex."
Advertisement
